logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Says International Study Affirms Xarelto's Benefits In Venous Blood Clots

Bayer HealthCare, a subsidiary of the German conglomerate Bayer AG (BAYRY.PK,BAYZF.PK), Tuesday said an international study that examined the safety and efficacy of Xarelto (rivaroxaban) in preventing potentially deadly venous blood clots reaffirmed the benefits of the drug.

The study, which Bayer calls real-world XAMOS study, assessed rivaroxaban in preventing venous blood clots (venous thromboembolism) in adults, following elective total hip or knee replacement surgery. The study reaffirmed the benefits of the oral, once-daily anticoagulant in everyday clinical practice.

Bayer also said XAMOS supports the clinical findings of and earlier trial programme, which showed oral, once-daily rivaroxaban to have consistently superior efficacy as well as a comparable and good safety profile to injectable enoxaparin.

Rivaroxaban, marketed under the brand name Xarelto, was discovered in Bayer HealthCare's Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Janssen Research & Development, LLC.

A.G.G. Turpie, Professor of Medicine, McMaster University, Canada and Chairman of the XAMOS Executive Steering Committee stated, "As the largest analysis of everyday clinical experience with a new oral anticoagulant, XAMOS offers real-world evidence and confidence that oral, once-daily rivaroxaban is safe and effective in protecting against dangerous blood clots in the orthopaedic setting - and importantly without the inconvenience and discomfort of current standard injectable treatments."

The non-interventional XAMOS study compared outcomes observed in everyday clinical practice across 17,413 orthopaedic patients receiving rivaroxaban or conventional pharmacological treatments for blood clot prevention.

The incidence of symptomatic thromboembolic events was lower in patients treated with rivaroxaban compared with conventional therapy.

In the U.S., rivaroxaban is available since July 2011 and Janssen Pharmaceuticals, Inc., a Johnson & Johnson unit, holds marketing rights.

Last week, Bayer HealthCare said it has submitted an application to the European Medicines Agency seeking marketing authorization for Xarelto. In mid-January, Bayer announced that Xarelto has been approved by the Japanese Ministry of Health, Labor and Welfare.

On Frankfurt's Xetra, Bayer shares are currently trading at 51.84 euros, up 1.77 percent, on a volume of 764 thousand shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Heading into a quiet week that precedes the final FOMC meeting of the year, the economic momentum remains strong. Data releases from the just concluded week makes it tough for the central bank to pass up an interest rate hike. However, will the Fed risk a backlash in a transition period on the political... AutoZone, Inc., an automotive replacement parts retailer, reported Tuesday higher profit in its first quarter with increased net sales and domestic store sales. Earnings per share topped analysts' estimates, while top line missed the view. In the pre-market activity on the NYSE, AutoZone shares were gaining 1.10 percent. The Justice Department, in the antitrust trial against the proposed Aetna- Humana Merger, argued that the merger would harm senior citizens who buy private Medicare plans. The U.S. Department of Justice stated that the merger would also harm consumers who buy plans on Affordable Care Act marketplaces, reports said. However, healthcare insurers Aetna And Humana defended their proposed merger..
comments powered by Disqus
Follow RTT